The Southeast Asia region is rich with narratives of digital transformation, yet few medical AI firms can translate these stories into tangible cash flows. XUNFEIHEALTH (ASX: 02506) appears to be one of those few. On June 17th, the company announced a strategic collaboration with PT DSST Mas Gemilang, a digital infrastructure technology investment platform under Indonesia's Sinar Mas Group. This partnership aims to export its full-stack AI medical technology to Southeast Asia, leveraging the technical moat of its Spark Medical Large Model V3.5. On the surface, this is a standard overseas cooperation memorandum. However, when viewed within the broader context of the global medical AI industry landscape and the overseas expansion of Chinese enterprises, it represents a historic milestone for China's medical AI sector, transitioning from "technical validation" to "scaled commercial deployment." This move also propels XUNFEIHEALTH into a more rigorous arena: the long-haul process of procurement and compliance within multinational public health systems.

Strategic Breakthrough: Using Indonesia as a Lever for the ASEAN Market

For this venture, XUNFEIHEALTH has chosen a distinctive path. Indonesia, serving as both the demographic and economic hub of ASEAN with a population exceeding 270 million, faces challenges of weak primary care capabilities and uneven distribution of medical resources—situations reminiscent of China several years ago. This presents a "golden opportunity" where AI medical technology can deliver maximum value. Instead of opting for piecemeal technology exports, the company has adopted a deep-integration model of "full-stack technology foundation + local ecosystem partnership." On one hand, as a scarce full-stack medical AI player on the Hong Kong market, XUNFEIHEALTH distinguishes itself from companies focused on single modalities like imaging or voice, having achieved commercial deployment of a multi-modal medical large model integrating voice, imaging, and medical text. For this collaboration, the company is exporting mature solutions validated by over 600 tiered hospitals and more than 77,000 primary care institutions in China, including flagship products like the AI Medical Assistant and AI Resident Health Profile. These solutions have been showcased at two consecutive World Health Assemblies and received official endorsement from China's National Health Commission, with their technical prowess and implementation efficacy already gaining international recognition.

On the other hand, the company has forged a deep partnership with Indonesia's leading conglomerate, Sinar Mas Group. By leveraging Sinar Mas's established government and corporate channels, digital infrastructure, and compliance capabilities, XUNFEIHEALTH effectively addresses the most daunting market access and regulatory barriers in emerging markets. The collaboration spans six core areas: intelligent diagnosis and treatment, public health monitoring, intelligent imaging, and medical digitalization, covering scenarios from local clinics to national-level public health platforms. This aligns highly with the company's existing product matrix, allowing for minimal marginal expansion costs. This combined "technology + ecosystem" approach not only ensures rapid penetration in Indonesia but also creates a replicable model for other Belt and Road countries like Malaysia, Thailand, and Singapore. Using Indonesia as a strategic pivot, XUNFEIHEALTH is methodically expanding across the entire ASEAN market, clearly outlining a secondary growth curve overseas.

Technological Moat: The Spark Large Model as the Foundation for Global Expansion

The core confidence for this international push stems from the newly iterated Spark Medical Large Model V3.5, which is also a key aspect of the market's undervaluation of XUNFEIHEALTH—many investors merely view it as a medical software service provider, overlooking the exclusive barrier created by its vertical medical large model. Technically, the company has pioneered optimizations in DSA dynamic sparse attention and MTP multi-token prediction algorithms on a fully domestic computing platform, boosting medical long-context reasoning throughput by 4.5 times. Relying on a unique data flywheel built from 1.6 billion anonymized medical voice records and 1.2 billion real-world diagnosis and treatment data points, with 2.2 million new clinical samples added daily for continuous model iteration, it surpasses international mainstream large models like GPT-5.5 and DeepSeek-V4-Pro across core metrics such as medical Q&A, multi-modal imaging, and evidence-based diagnosis.

The implementation results are quantifiable and verifiable: a 91% doctor adoption rate for medical record generation in top-tier hospitals and a 75% adoption rate for intelligent imaging reports. Several products have率先突破 industry practicality thresholds, moving beyond the "lab technology, hard to commercialize" dilemma faced by many AI firms. More importantly, unlike the industry's common practice of "PPT-based expansion" or selling isolated algorithms, XUNFEIHEALTH is exporting a complete, nationally project-validated ecosystem. From AI systems for the full disease cycle to national-level epidemic monitoring platforms, and from intelligent imaging to digital upgrades for medical institutions, the company provides "turnkey" solutions. This model not only fosters extremely high customer stickiness and controllable marginal expansion costs but also builds a deep competitive moat that is difficult for latecomers to bridge.

Market Reassessment: An Undervalued Leader Poised for a Double Boost

Comparing valuations within the Hong Kong-listed AI medical sector, the average 2026 price-to-sales ratio for comparable companies exceeds 12x, while XUNFEIHEALTH currently trades at a PS ratio of around 7x, positioning it at the lower end of the sector's valuation range and indicating a clear valuation mismatch. The market's undervaluation stems from three core cognitive biases: first, underestimating the vertical technical barrier of the Spark Medical Large Model, simplistically categorizing the company as a generic medical informatization firm; second, overlooking the incremental second growth curve potential from Southeast Asian expansion, pricing it based solely on domestic market potential; and third, failing to fully appreciate the long-term moat formed by its massive real-world medical data, underestimating the sustained iterative advantage from its data flywheel.

Looking at global benchmarks, AI unicorn OpenEvidence currently holds a valuation of $12 billion. In contrast, XUNFEIHEALTH possesses established B2B and government healthcare service experience and scenario access that OpenEvidence has yet to penetrate. Combined with its proven domestic commercialization track record, fully domestic and proprietary technology, and vast overseas blue-ocean market potential—all scarce attributes—the company has ample room for valuation repair. Multiple upcoming catalysts are expected to drive this reassessment: the gradual release of order confirmations from the Indonesia project, continuous iteration and upgrades of the Spark Medical Large Model, increasing repeat orders from domestic top-tier hospitals, replication of the model in other ASEAN countries, and rapid user growth in its consumer-facing health management business.

Conclusion

From Hefei to Jakarta, XUNFEIHEALTH is charting a new path of globalization for Chinese AI medical enterprises. It is no longer merely a participant in China's domestic medical infrastructure development but is emerging as an exporter of Chinese solutions for global medical digital transformation. As its overseas operations continue to expand, this undervalued leader in AI healthcare is approaching a historic moment of value recognition and reassessment. The current secondary market has not yet fully priced in its global growth potential and exclusive technological barriers, leaving the stock at a historically low valuation point. Short-term catalysts from overseas project deployments are expected to drive market activity, while medium to long-term performance and valuation are poised for a double boost, supported by dual growth curves from domestic and international markets, presenting high investment value.